Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SwanBio Therapeutics

https://www.swanbiotx.com/

Latest From SwanBio Therapeutics

Beacon Eye Gene Therapy Efforts Buoyed By Cash Boost

In a major boost for the UK biotech sector, an impressive sum has been raised by Beacon Therapeutics to support its R&D activities in ophthalmic gene therapies.

Ophthalmic Financing

€80m Cash Boost Helps iOnctura Accelerate Eye Cancer Candidate

The proceeds from the impressive series B financing will help progress roginolisib through Phase II trials.

Cancer Financing

Two Better Than One As Syncona Creates Spur

The merger of Freeline and SwanBio is establishing an entity with secure financing to advance their respective gene therapies for Gaucher’s disease and adrenomyeloneuropathy.

M & A Gene Therapy

Deal Watch: Cidara Licenses US Rights To Antifungal Under FDA Review To Melinta

Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register